GlassScriptPhysician profile
Swati Pradeep
NPI 1730560640
$16,961.72
in general payments reported to CMS, 2019-2025
41 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,980 · 2020: $692 · 2021: $1,455 · 2022: $1,902 · 2023: $1,832 · 2024: $1,323 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,799 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,798.82 |
| Education | $134.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $7,842.88 | 2019-2020 | |
| Abbvie INC. | $1,602.65 | 2021-2025 | |
| Abbott Laboratories | $1,365.35 | 2020-2024 | Infinity |
| Neurocrine Biosciences, INC. | $821.85 | 2020-2025 | Ingrezza, Ongentys |
| Medtronic, INC. | $783.19 | 2021-2025 | Activa PC, Percept PC Brainsense |
| Teva Pharmaceuticals USA, INC. | $775.25 | 2019-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $766.66 | 2020-2025 | Nuplazid, Daybue |
| Supernus Pharmaceuticals, INC. | $358.95 | 2022-2024 | Qelbree |
| Boston Scientific Corporation | $273.58 | 2021-2024 | |
| Allergan, INC. | $268.75 | 2019-2022 | |
| Acorda Therapeutics, INC | $190.49 | 2019-2022 | |
| Kyowa Kirin, INC. | $181.46 | 2021-2023 | Nourianz |
| Lundbeck LLC | $175.35 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $169.55 | 2021-2023 | Rytary |
| Eisai INC. | $168.96 | 2023-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $142.94 | 2021-2025 | Skyclarys, Vumerity, Tysabri |
| Merz Pharmaceuticals, LLC | $117.03 | 2021-2025 | Inbrija, Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2022-2025 | Hyqvia |
| Ipsen Biopharmaceuticals, INC | $96.00 | 2023-2024 | Dysport |
| Merz North America, INC. | $87.01 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $77.43 | 2019-2021 | |
| Mdd US Operations, LLC | $70.34 | 2024-2025 | Apokyn, Gocovri |
| Novartis Pharmaceuticals Corporation | $56.51 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $54.01 | 2023-2024 | Nuedexta, Rexulti |
| Genentech USA, INC. | $52.30 | 2025 | Ocrevus Zunovo |
| Ucb, INC. | $47.12 | 2022-2025 | Rystiggo |
| Avion Pharmaceuticals | $41.09 | 2022-2023 | Dhivy |
| Alexion Pharmaceuticals, INC. | $24.95 | 2023 | Ultomiris |
| Lilly USA, LLC | $23.79 | 2024 | Emgality |
| Jazz Pharmaceuticals INC. | $23.41 | 2024 | |
| C2n Diagnostics, LLC | $23.02 | 2025 | Precivityad2 |
| Springworks Therapeutics, INC. | $21.94 | 2025 | |
| Corium, LLC | $21.77 | 2022 | |
| Ge Healthcare | $20.01 | 2021 | |
| Amgen INC. | $19.05 | 2022 | |
| Csl Behring | $18.42 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.01 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.82 | 2024 | Ponvory |
| Genzyme Corporation | $16.82 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $13.26 | 2022 | |
| Saol Therapeutics INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Pradeep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.